Germline variation in RASAL2 may predict survival in patients with RAS-activated colorectal cancer.
Christopher WillsKatie WattsTimothy S MaughanDavid J FisherNada A Al-TassanRichard S HoulstonValentina Escott-PriceJeremy P CheadlePublished in: Genes, chromosomes & cancer (2023)
Our data demonstrate a prognostic role for RASAL2 in patients with MAPK-activated CRCs, with potential as a therapeutic target.